Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 4663 (MIR4663) is a member of the human microRNA gene family and produces a short non-coding RNA that modulates gene expression post-transcriptionally. Like other miRNAs, MIR4663 is transcribed as a primary miRNA transcript, processed in the nucleus by Drosha/DGCR8, exported as precursor miRNA, and further processed by Dicer in the cytoplasm to yield the mature form. The mature MIR4663 is loaded into the RNA-induced silencing complex (RISC), guiding it to partially complementary targets in the 3'-UTR of mRNAs, resulting in either mRNA degradation or inhibition of translation[1][5][6]. MiRNAs regulate diverse biological processes including cell proliferation, apoptosis, and development, and can act as oncogenes or tumor suppressors depending on cellular context[1][3][6]. Specific roles of MIR4663 have not been extensively characterized in the literature, but emerging evidence suggests miRNAs generally have profound effects across disease states and are being investigated as biomarkers and candidates for therapeutic modulation[1][3].
Not established for MIR4663; For miRNAs in general: gene silencing via mRNA degradation or translational inhibition
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 4663 (MIR4663).